Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy

Pharmacotherapy

Volumn 28, Issue 1, 2008, Pages 35-41

  Lin, Chun Jung ^a   Yen, Ming Fang ^b   Hu, Oliver Yoa Pu ^c   Lin, Min Shung ^d   Hsiong, Cheng Huei ^c   Hung, Chin Chuan ^a   Liou, Horng Huei ^a,e,f  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^d CATHAY GENERAL HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f NONE   (Taiwan)

Author keywords

CYP2C19 genotype; CYP2C9 genotype; Galactose single point test; Gingival hyperplasia; GSP; Liver function tests; Phenytoin

Indexed keywords

5 (4' HYDROXYPHENYL) 5 PHENYLHYDANTOIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; DRUG METABOLITE; GALACTOSE; GAMMA GLUTAMYLTRANSFERASE; PHENYTOIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DISEASE SEVERITY; DRUG METABOLISM; ENZYME POLYMORPHISM; EPILEPSY; FEMALE; GENOTYPE; GINGIVA HYPERPLASIA; HEPATITIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT;

ADULT; ALKALINE PHOSPHATASE; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EPILEPSIES, PARTIAL; FEMALE; GALACTOSE; GAMMA-GLUTAMYLTRANSFERASE; GENOTYPE; GINGIVAL HYPERPLASIA; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; ODDS RATIO; PHENYTOIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 38049075374     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.1.35     Document Type: Article

References (40)

1. Kimball OP. The treatment of epilepsy with sodium diphenyl hydantoinate. JAMA 1939;112:1244-5.
2. Dongari-Bagtzoglou A. Drug-associated gingival enlargement. J Periodontol 2004;75:1424-31.
3. Angelopoulos AP, Goaz PW. Incidence of diphenylhydantoin gingival hyperplasia. Oral Surg Oral Med Oral Pathol 1972;34:898-906.
4. Thomason JM, Seymour RA, Rawlins MD. Incidence and severity of phenytoin-induced gingival overgrowth in epileptic patients in general medical practice. Community Dent Oral Epidemiol 1992;20:288-91.
5. Güncü GN, Çaglayan F, Dinçel A, Bozkurt A, Saygi S, Karabulut E. Plasma and gingival crevicular fluid phenytoin concentrations as risk factors for gingival overgrowth. J Periodontol 2006;77:2005-10.
6. Soga Y, Nishimura F, Ohtsuka Y, et al. CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects. Life Sci 2004;74:827-34.
7. Majola MP, McFadyen ML, Connolly C, Nair YP, Govender M, Laher MH. Factors influencing phenytoin-induced gingival enlargement. J Clin Periodontol 2000;27:506-12.
8. Zhou LX, Pihlstrom B, Hardwick JP, Park SS, Wrighton SA, Holtzman JL. Metabolism of phenytoin by the gingiva of normal humans: the possible role of reactive metabolites of phenytoin in the initiation of gingival hyperplasia. Clin Pharmacol Ther 1996;60:191-8.
9. Kuru L, Yilmaz S, Kuru B, Köse KN, Noyan Ü. Expression of growth factors in the gingival crevice fluid of patients with phenytoin-induced gingival enlargement. Arch Oral Biol 2004;49:945-50.
10. Yamada H, Nishimura F, Naruishi K, et al. Phenytoin and cyclosporine A suppress the expression of MMP-1, TIMP-1, and cathepsin L, but not cathepsin B in cultured gingival fibroblasts. J Periodontol 2000;71:955-60.
11. Ieiri I, Goto W, Hirata K, et al. Effect of 5-(p-hydroxyphenyl)-5- phenylhydantoin (p-HPPH) enantiomers, major metabolites of phenytoin, on the occurrence of chronic-gingival hyperplasia: in vivo and in vitro study. Eur J Clin Pharmacol 1995;49:51-6.
12. Fritz S, Lindner W, Roots I, Frey BM, Kupfer A. Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. J Pharmacol Exp Ther 1987;241:615-22.
13. Bajpai M, Roskos LK, Shen DD, Levy RH. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 1996;24:1401-3.
14. Ieiri I, Mamiya K, Urae A, et al. Stereoselective 4′-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese. Br J Clin Pharmacol 1997;43:441-5.
15. Cuttle L, Munns AJ, Hogg NA, et al. Phenytoin metabolism by human cytochrome P450: involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation. Drug Metab Dispos 2000;28:945-50.
16. Martin E, Tozer TN, Sheiner LB, Riegelman S. The clinical pharmacokinetics of phenytoin. J Pharmacokinet Biopharm 1977;5:579-96.
17. Murray M. P450 enzymes: inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet 1992;23:132-46.
18. Hoyumpa AM, Trevino-Alanis H, Grimes I, Humphries TJ. Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis. Clin Ther 1999;21:691-701.
19. Hu OY, Tang HS, Chang CL. Novel galactose single point method as a measure of residual liver function: example of cefoperazone kinetics in patients with liver cirrhosis. J Clin Pharmacol 1995;35:250-8.
20. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizure. Epilepsia 1981;22:489-501.
21. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-99.
22. Miller CS, Damm DD. Incidence of verapamil-induced gingival hyperplasia in a dental population. J Periodontol 1992;63:453-6.
23. Tang HS, Hu OY. Assessment of liver function using a novel galactose single point method. Digestion 1992;52:222-31.
24. Hu OY, Hu TM, Tang HS. Determination of galactose in human blood by high-performance liquid chromatography: comparison with an enzymatic method and application to the pharmacokinetic study of galactose in patients with liver dysfunction. J Pharm Sci 1995;84:231-5.
25. Eto S, Noda H, Noda A. Simultaneous determination of antiepileptic drugs and their metabolites, including chiral compounds, via β-cyclodextrin inclusion complexes by a column-switching chromatographic technique. J Chromatogr B Biomed Appl 1994;658:385-90.
26. Wang SL, Huang JD, Lai MD, Tsai JJ. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995;5:37-42.
27. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenyloin metabolism in humans. J Biol Chem 1994;269:15419-22.
28. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8.
29. Jordan CD, Flood JG, Laposata M, Lewandrowski KB. Case records of the Massachusetts General Hospital weekly clinicopathological exercises. Normal reference laboratory values. N Engl J Med 1992;327:718-24.
30. Andreasen PB, Lyngbye J, Trolle E. Abnormalities in liver function tests during long-term diphenylhydantoin therapy in epileptic outpatients. Acta Med Scand 1973;194:261-4.
31. Aiges HW, Daum F, Olson M, Kahn E, Teichberg S. The effects of phenobarbital and diphenylhydantoin on liver function and morphology. J Pediatr 1980;97:22-6.
32. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury 1. Performance characteristics of laboratory tests. Clin Chem 2000;46:2027-49.
33. Henderson JM, Kutner MH, Bain RP. First-order clearance of plasma galactose: the effect of liver disease. Gastroenterology 1982;83:1090-6.
34. Saito K, Mori S, Iwakura M, Sakamoto S. Immunohistochemical localization of transforming growth factor-β, basic fibroblast growth factor and heparan sulphate glycosaminoglycan in gingival hyperplasia induced by nifedipine and phenytoin. J Periodontal Res 1996;31:545-55.
35. Dill RE, Miller EK, Weil T, Lesley S, Farmer GR, Iacopino AM. Phenytoin increases gene expression for platelet-derived growth factor B chain in macrophages and monocytes. J Periodontol 1993;64:169-73.
36. Iacopino AM, Doxey D, Cutler CW, et al. Phenytoin and cyclosporine A specifically regulate macrophage and expression of platelet-derived growth factor and interleukin-1 in vitro and in vivo: possible mechanism of drug-induced overgrowth. J Periodontol 1997;68:73-83.
37. Das SJ, Olsen I. Keratinocyte growth factor is upregulated by the hyperplasia-inducing drug nifedipine. Cytokine 2000;12:1566-9.
38. Das SJ, Newman HN, Olsen I. Keratinocyte growth factor receptor is up-regulated in cyclosporine A-induced gingival hyperplasia. J Dent Res 2002;81:683-7.
39. Steiling H, Muhlbauer M, Bataille F, Scholmerich J, Werner S, Hellerbrand C. Activated hepatic stellate cells express keratinocyte growth factor in chronic liver disease. Am J Pathol 2004;165:1233-41.
40. Housley RM, Morris CF, Boyle W, et al. Keratinocyte growth factor induces proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract. J Clin Invest 1994;94:1764-77.